DNTH — Dianthus Therapeutics Inc. stock price and chart

Share this page

DNTH

$72.09-3.27%

as of close, Oct 16, 2026

☾ AH $72.09 -3.27%

Dianthus Therapeutics Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.010%US Stock Market 0.007%Russell 3000 0.006%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jun 27, 2018

VolumeEEEE

20182020202220242026

50.0100.0150.0200.0250.0300.005.0M10.0M$72.09

2026-10-16

Price$72.09

MA20$96.30

MA50$75.38

Vol2.0M

What would $1,000 invested in DNTH be worth today? →

DNTH returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $72.09
YTD price return: +74.93%
YTD total return: +74.93%
Next earnings: Nov 4, 2026
Market cap: 4B2018-09 6.3B2026-10 4B-36.2% over the window
Enterprise value: 3.9B
Shares outstanding: 55.9M2017-12 2.4M2026-06 55.9M+2278.9% over the window
52W low: $32.22
52W high: $117.88
From 52W high: -38.84%
From 52W low: +123.74%
52W range: 47%

Volume

Rel volume: 1.14×
30D volume: 927.7K
30D $ vol: 84.8M

Fundamentals

EPS (ttm): -$4.112020-12 -$1.712026-06 -$4.11+140.6% over the window
FCF (ttm): -155.7M2016-12 -6.7M2026-06 -155.7M+2235.2% over the window
FCF/share: -$2.782017-12 -$10.402026-06 -$2.78-73.2% over the window
Book value/share: $20.952017-12 -$17.912026-06 $20.95-217.0% over the window
ROE: -16.40%2018-06 -23.1%2026-06 -16.4%-29.0% over the window
ROA: -15.85%2017-12 -65.2%2026-06 -15.8%-75.7% over the window
Current ratio: 26.102017-12 12.682026-06 26.10+105.9% over the window

Growth (CAGR, ttm) · 10Y

Sales: -67.37%2024-12-31 → 2025-12-316.2M → 2M (-67.3% total)n/an/an/a
Shares: +73.84%2025-06-30 → 2026-06-3032.2M → 55.9M (+73.8% total)-2.67%2023-06-30 → 2026-06-3060.7M → 55.9M (-7.8% total)-0.92%2021-06-30 → 2026-06-3058.6M → 55.9M (-4.5% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -76.43%2024-12-31 → 2025-12-31$0.19 → $0.05 (-76.4% total)n/an/an/a
Book value/share: +122.66%2025-06-30 → 2026-06-30$9.42 → $20.95 (+122.5% total)n/a+43.33%2021-06-30 → 2026-06-30$3.46 → $20.95 (+504.9% total)n/a
Price: +100.35%2025-10-16 → 2026-10-16$36.00 → $72.09 (+100.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+77.43%2023-10-16 → 2026-10-16$12.90 → $72.09 (+458.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-7.71%2021-10-15 → 2026-10-16$107.68 → $72.09 (-33.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +100.35%2025-10-16 → 2026-10-16$36.00 → $72.09 (+100.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+77.43%2023-10-16 → 2026-10-16$12.90 → $72.09 (+458.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-7.71%2021-10-15 → 2026-10-16$107.68 → $72.09 (-33.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -17.5×2018-09 -159.182026-10 -21.01-86.8% over the window
Fwd P/E: -17.9×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.4×2018-09 36.762026-10 3.45-90.6% over the window
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -3.86%2018-06 -0.5%2026-06 -2.9%+432.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 55.9M ÷ 32.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -73.84%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-73.84%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($599.7M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -73.84%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-308K) ÷ today's market cap ($4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -0.01%2018-06 0.0%2026-06 -0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-308K + TTM dividends $0) ÷ today's market cap ($4B). Same caveat as the cash buyback yield.: -0.01%2018-06 0.0%2026-06 -0.0%

Vs own 10Y history

P/B: 31st

Bar = where today’s multiple sits in DNTH’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-3.27%

-12.48%

-29.66%

-24.39%

YTD

+74.93%

+100.25%

-33.05%

Financial statements

Open full DNTH financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

DNTH — Dianthus Therapeutics Inc. price, chart and key statistics